Gwendolyn Gresham - 31 Dec 2024 Form 4 Insider Report for Core Laboratories Inc. /DE/ (CLB)

Role
SVP
Signature
/s/ Mark Tattoli, Attorney-in-Fact
Issuer symbol
CLB
Transactions as of
31 Dec 2024
Net transactions value
-$103,670
Form type
4
Filing time
03 Jan 2025, 16:57:53 UTC
Previous filing
15 Feb 2024
Next filing
13 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLB Common Stock Tax liability $103,670 -5,989 -18% $17.31 27,575 31 Dec 2024 Direct
transaction CLB Common Stock Options Exercise $0 +9,604 +40% $0.000000 33,564 31 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLB Performance Shares Options Exercise $0 -9,604 -100% $0.000000 0 31 Dec 2024 Common Stock 9,604 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024.